Merck & Co., Inc. (MRK)
| Market Cap | 196.23B |
| Revenue (ttm) | 63.62B |
| Net Income (ttm) | 16.41B |
| Shares Out | 2.50B |
| EPS (ttm) | 6.49 |
| PE Ratio | 12.11 |
| Forward PE | 8.58 |
| Dividend | $3.24 (4.12%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 12,234,731 |
| Open | 78.76 |
| Previous Close | 77.60 |
| Day's Range | 77.69 - 78.96 |
| 52-Week Range | 73.31 - 114.79 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 107.21 (+36.47%) |
| Earnings Date | Oct 30, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $107.21, which is an increase of 36.47% from the latest price.
News
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Merck: Game-Changing Oncology Drugs Power Stock Surge
Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-...
Merck: 25% Total Return CAGR Potential
Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like...
Merck's Keytruda gets an upgrade
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news.
Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape
CNBC's Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new va...
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AIDD--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeu...
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with onc...
Undercovered Dozen: Applied Digital, Merck, B2Gold And More
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Among today's stocks covered are B2Gold, Me...
FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYT...
US FDA approves Merck's new injectable version of Keytruda
The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient option of the wi...
EMA committee recommends approval for injectable version of Merck's Keytruda
The European Medicines Agency's committee has recommended the approval for a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, the U.S. drugmaker ...
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of RSV in Infants During Their First RSV Season.
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Produ...
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its mul...
Oakmark Funds' Bill Nygren: Here's where to look beyond the Mag 7
Bill Nygren, Oakmark Funds partner and CIO, joins CNBC's 'Closing Bell' to discuss where to find market opportunities outside of tech, why he's keeping an eye on Corebridge Financial and Delta Airline...
Merck: Buy This Dividend Powerhouse While It's Cheap
Merck offers a compelling opportunity for long-term income and value investors, trading near its 52-week low with a 4% dividend yield. MRK's robust drug pipeline, strong balance sheet, and strategic a...
Merck's pneumonia shot shows promise in late-stage study
Drugmaker Merck said on Thursday that its pneumonia shot showed strong immune responses in children and teens who are at higher risk of serious illness, based on results from a late-stage study presen...
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease.
Britain defends investment record as Merck scraps labs over pharma environment
Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging busi...
US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs
New blow to UK's key life science sector as industry body warns country is losing ground on investment and research
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Merck to scrap London drug research centre
Merck said on Wednesday it was scrapping research operations in London, citing the UK's challenging business environment.